Targeted DNA Demethylation: Vectors, Effectors and Perspectives.

Area of Science:

• Epigenetics and Molecular Biology
• Genomic Medicine
• Gene Therapy

Background:

• Aberrant DNA hypermethylation is implicated in numerous diseases, including cancer and cardiovascular, neurological, and autoimmune disorders.
• Current genome-wide DNA demethylation methods are insufficient for treating diseases with specific epimutations.
• Gene-specific epigenetic editing is crucial for reactivating silenced genes and understanding epigenetic alterations.

Purpose of the Study:

• To review current and potential strategies for gene-specific DNA demethylation.
• To highlight the potential of epigenetic editing as a therapeutic approach.
• To discuss challenges and future directions in the field.

Main Methods:

• Utilizing sequence-dependent DNA-binding molecules like zinc finger protein arrays (ZFA), transcription activator-like effectors (TALE), and CRISPR/dCas9.
• Engineering synthetic proteins by fusing DNA-binding domains with DNA demethylases (e.g., ten-eleven translocation (Tet), thymine DNA glycosylase (TDG)).
• Assessing the induction or enhancement of transcriptional responsiveness at targeted loci.

Main Results:

• Synthetic proteins successfully induced site-specific DNA demethylation and transcriptional activation.
• Demonstrated the feasibility of targeting specific genes for epigenetic modification.
• Identified challenges such as the need for transgenesis for construct delivery.

Conclusions:

• Gene-specific DNA demethylation via epigenetic editing presents a promising therapeutic strategy.
• This approach allows for precise targeting of epimutations, unlike genome-wide methods.
• Further research is needed to overcome delivery challenges and optimize therapeutic applications.